Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information

American Journal of Hematology
Valentina NardiRobert P Hasserjian

Abstract

Bone marrow (BM) evaluation is an important part of lymphoma staging, which guides patient management. Although positive staging marrow is defined as morphologically identifiable disease, such samples often also include flow cytometric analysis and conventional karyotyping. Cytogenetic analysis is a labor-intensive and costly procedure and its utility in this setting is uncertain. We retrospectively reviewed pathological reports of 526 staging marrow specimens in which conventional karyotyping had been performed. All samples originated from a single institution from patients with previously untreated Hodgkin and non-Hodgkin lymphomas presenting in an extramedullary site. Cytogenetic analysis revealed clonal abnormalities in only eight marrow samples (1.5%), all of which were positive for lymphoma by morphologic evaluation. Flow cytometry showed a small clonal lymphoid population in three of the 443 morphologically negative marrow samples (0.7%). Conventional karyotyping is rarely positive in lymphoma staging marrow samples and, in our cohort, the BM karyotype did not contribute clinically relevant information in the vast majority of cases. Our findings suggest that karyotyping should not be performed routinely on BM samples tak...Continue Reading

References

Mar 1, 1984·Journal of Clinical Pathology·R BartlG Hoffmann-Fezer
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Oct 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K J SavageJ M Connors
Jun 2, 2011·Journal of Biomedicine & Biotechnology·Antonella BardiAntonio Cuneo
May 2, 2012·Advances in Hematology·Sylvia Hoeller, Christiane Copie-Bergman
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H TillyUNKNOWN ESMO Guidelines Working Group
Jul 3, 2013·Cytogenetic and Genome Research·A SimonsR J Hastings
Jul 31, 2013·Current Hematologic Malignancy Reports·Pei Lin, L Jeffrey Medeiros
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Sep 30, 2014·Acta Oncologica·Hugo J A AdamsThomas C Kwee

❮ Previous
Next ❯

Citations

Mar 5, 2016·Surgical Pathology Clinics·Kaaren K Reichard, Adam J Wood
Jun 5, 2020·The Cancer Journal·James P Solomon, Maria E Arcila

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.